Treatment effects in various subsets
| Subset | RXArm | #Pts | Median OSMonths | 3-year OS | P value |
|---|---|---|---|---|---|
| Measurable | DCV | 8 | 17.6 | 38% | 0.122 |
| TCV | 9 | 9.0 | 11% | ||
| Not Measurable | DCV | 10 | 44.6 | 80% | 0.332 |
| TCV | 15 | 32.2 | 33% | ||
| Not NED | DCV | 14 | 25.2 | 50% | 0.011 |
| TCV | 13 | 9.9 | 8% | ||
| NED | DCV | 4 | 53.0 | 75% | 0.561 |
| TCV | 11 | 33.7 | 40% | ||
| High LDH St 4 | DCV | 6 | 17.6 | 17% | 0.010 |
| TCV | 3 | 1.1 | 0% | ||
| WNL LDH | DCV | 11 | 53.0 | 82% | 0.079 |
| TCV | 20 | 21.1 | 25% | ||
| KPS =100 | DCV | 9 | 44.6 | 67% | 0.810 |
| TCV | 12 | 32.2 | 33% | ||
| KPS < 100 | DCV | 9 | 38.6 | 56% | 0.303 |
| TCV | 12 | 9.0 | 17% | ||
| Stage 4 | DCV | 16 | 38.6 | 56% | 0.292 |
| TCV | 17 | 16.9 | 24% | ||
| Stage 3 | DCV | 2 | > 60 | 100% | 0.141 |
| TCV | 7 | 32.2 | 29% |
RX arm treatment arm, Pts patients, OS overall survival, DCV dendritic cell vaccine, TCV = tumor cell vaccine, NED no evidence of disease, LDH serum lactate dehydrogenase, St 4 stage 4, KPS Karnofsky Performance Status